Survey on symptoms in patients receiving chemotherapy in an Italian department of oncology: a comparison between period prevalences.
Adult
Aged
Aged, 80 and over
Alopecia
/ chemically induced
Antineoplastic Agents
/ adverse effects
Constipation
/ chemically induced
Drug-Related Side Effects and Adverse Reactions
/ epidemiology
Fatigue
/ chemically induced
Female
Humans
Italy
/ epidemiology
Male
Middle Aged
Nausea
/ chemically induced
Neoplasms
/ drug therapy
Patients
Prevalence
Self-Assessment
Surveys and Questionnaires
Young Adult
Chemotherapy
Prevalence
Self-assessment
Symptom
Journal
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
ISSN: 1433-7339
Titre abrégé: Support Care Cancer
Pays: Germany
ID NLM: 9302957
Informations de publication
Date de publication:
Jan 2021
Jan 2021
Historique:
received:
17
06
2019
accepted:
20
04
2020
pubmed:
30
4
2020
medline:
15
12
2020
entrez:
30
4
2020
Statut:
ppublish
Résumé
The purpose of this study is to evaluate the prevalence over time of the measured side effects using a self-assessment questionnaire in normal clinical practice. The prevalence of symptoms reported by patients on the questionnaire was evaluated over two 1-year periods: from 1 June 2006 to 31 May 2007 and from 1 July 2013 to 30 June 2014. Descriptive statistics were used to describe population. The 2006-2007 and 2013-2014 datasets were compared with each other using the chi-squared test for equality of proportion, Pearson's chi-squared test, and chi-squared test for trend in proportion. We analyzed 1974 questionnaires from 283 patients in 2006-2007 and 2619 questionnaires from 403 patients in 2013-2014. The most frequently encountered symptom in both periods was fatigue; nausea and constipation decreased in 2013-2014 compared with 2006-2007, while alopecia increased. Using the self-assessment questionnaire in normal clinical practice has allowed us to carry out an accurate prevalence survey on symptoms in patients receiving chemotherapy that takes into account not only reports of the presence of symptoms but also of their absence. Between 2006-2007 and 2013-2014, there was an increase in patients treated at the Oncological Day Hospital of the Biella Hospital, whose characteristics were comparable in the two periods, except for the type of therapies carried out. Some symptoms were in decline: fatigue, nausea, and constipation.
Identifiants
pubmed: 32346798
doi: 10.1007/s00520-020-05486-x
pii: 10.1007/s00520-020-05486-x
doi:
Substances chimiques
Antineoplastic Agents
0
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
255-261Références
Wagland R, Richardson A, Armes J, Hankins M, Lennan E, Griffiths P (2015) Treatment-related problems experienced by cancer patients undergoing chemotherapy: a scoping review. Eur J Cancer Care 24:605–617
doi: 10.1111/ecc.12246
Di Maio M, Gallo C, Leighl NB et al (2015) Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials. J Clin Oncol 33:910–915
doi: 10.1200/JCO.2014.57.9334
Petersen MA, Larsen H, Pedersen L, Sonne N, Groenvold M (2006) Assessing health-related quality of life in palliative care: comparing patient and physician assessments. Eur J Cancer 42:1159–1166
doi: 10.1016/j.ejca.2006.01.032
Fromme EK, Eilers KM, Mori M, Hsieh YC, Beer TM (2004) How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the Quality-of-Life Questionnaire C30. J Clin Oncol 22:3485–3490
doi: 10.1200/JCO.2004.03.025
Basch E, Iasonos A, McDonough T, Barz A, Culkin A, Kris MG, Scher HI, Schrag D (2006) Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study. Lancet Oncol 7:903–909
doi: 10.1016/S1470-2045(06)70910-X
Giesinger JM, Wintner LM, Zabernigg A, Gamper EM, Oberguggenberger AS, Sztankay MJ, Kemmler G, Holzner B (2014) Assessing quality of life on the day of chemotherapy administration underestimates patients’ true symptom burden. BMC Cancer 14:758
doi: 10.1186/1471-2407-14-758
Velikova G, Booth L, Smith AB, Brown PM, Lynch P, Brown JM, Selby PJ (2004) Measuring quality of life in routine oncology practice improves communication and patient well-being: a randomized controlled trial. J Clin Oncol 22:714–724
doi: 10.1200/JCO.2004.06.078
Office of Disease Prevention and Health Promotion US Department of Health and Human Services (1999) Wired for health and well-being: the emergence of interactive health communication. Science Panel on Interactive Communication and Health. US Government Printing Office, Washington
Acquadro C, Berzon R, Dubois D, Leidy NK, Marquis P, Revicki D, Rothman M, PRO Harmonization Group (2003) Incorporating the patient’s perspective into drug development and communication: an ad hoc task force report of the Patient-Reported Outcomes [PRO] Harmonization Group meeting at the Food and Drug Administration, Feb 16, 2001. Value Health 6:522–531
doi: 10.1046/j.1524-4733.2003.65309.x
Wiklund I (2004) Assessment of patient-reported outcomes in clinical trials: the example of health-related quality of life. Fundam Clin Pharmacol 18:351–363
doi: 10.1111/j.1472-8206.2004.00234.x
Fairclough DL (2004) Patient reported outcomes as endpoints in medical research. Stat Methods Med Res 13:115–138
doi: 10.1191/0962280204sm357ra
Patrick DL, Ferketich SL, Frame PS, Harris JJ, Hendricks CB, Levin B, Link MP, Lustig C, McLaughlin J, Ried LD, Turrisi AT 3rd, Unützer J, Vernon SW, National Institutes of Health State-of-the-Science Panel (2003) National Institutes of Health State-of-the-Science conference statement: symptom management in cancer: pain, depression, and fatigue, July 15–17, 2002. J Natl Cancer Inst 95:1110–1117
doi: 10.1093/jnci/djg014
Sneeuw KC, Sprangers MA, Aaronson NK (2002) The role of health care providers and significant others in evaluating the quality of life of patients with chronic disease. J Clin Epidemiol 55:1130–1143
doi: 10.1016/S0895-4356(02)00479-1
Sprangers MA, Sneeuw KC (2000) Are healthcare providers adequate raters of patients’ quality of life – perhaps more than we think? Acta Oncol 39:5–8
doi: 10.1080/028418600430914
Groenvold M, Klee MC, Sprangers MA, Aaronson NK (1997) Validation of the EORTC QLQ-C30 quality of life questionnaire through combined qualitative and quantitative assessment of patient observer agreement. J Clin Epidemiol 50:441–450
doi: 10.1016/S0895-4356(96)00428-3
Vogelzang NJ, Breitbart W, Cella D et al (1997) Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of an assessment survey. The fatigue coalition. Semin Hematol 34(suppl 2):4–12
Sloan JA, Cella D, Hays RD (2005) Clinical significance of patient reported questionnaire data: another step toward consensus. J Clin Epidemiol 58:1217–1219
doi: 10.1016/j.jclinepi.2005.07.009
Bent S, Padula A, Avins AL (2006) Brief communication: better ways to question patients about adverse medical events: a randomized, controlled trial. Ann Intern Med 144:257–261
doi: 10.7326/0003-4819-144-4-200602210-00007
Kirkova J, Davis MP, Walsh D, Tiernan E, O'Leary N, LeGrand SB, Lagman RL, Russell KM (2006) Cancer symptom assessment instruments: a systematic review. J Clin Oncol 24:1459–1473
doi: 10.1200/JCO.2005.02.8332
Morris LA, Miller DW (2002) The regulation of patient-reported outcome claims: need for a flexible standard. Value Health 5:372–381
doi: 10.1046/j.1524-4733.2002.54073.x
Velikova G, Wright P, Smith AB, Stark D, Perren T, Brown J, Selby P (2001) Self-reported quality of life of individual cancer patients: concordance of results with disease course and medical records. J Clin Oncol 19:2064–2073
doi: 10.1200/JCO.2001.19.7.2064
National Cancer Institute (2013) NCI guidelines for investigators: adverse event reporting requirements for DCTD (CTEP and CIP) and DCP INDs and IDEs. National Cancer Institute, Bethesda
https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf . Accessed 16 June 2017
Bash E, Iasonos A, McDonough T et al (2006) Patients versus clinician symptom reporting using the National Cancer Institute Common Toxicity Criteria for Adverse Events: results of a questionnaire-based study. Lancet Oncol 7:903–909
doi: 10.1016/S1470-2045(06)70910-X
Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman CN, Rubin P (2003) CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 13:176–181
doi: 10.1016/S1053-4296(03)00031-6
Wittekind Ch, Greene FL, Hutter RVP, Klimpfinger M, Sobin LH (2004) Atlante TNM, V Edizione, Edizioni Minerva Medica, Torino
L’Informatore Farmaceutico (2013) Edizioni Elsevier, Milano
http://www.epiprev.it/sites/default/files/001_054%20Prime%20pagine.pdf . Accessed 16 June 2017
http://www.registri-tumori.it/PDF/AIOM2014/I_numeri_del_cancro_2014.pdf . Accessed 16 June 2017
Schwartzberg L (2014) Addressing the value of novel therapies in chemotherapy-induced nausea and vomiting. Expert Rev Pharmacoecon Outcomes Res 14:825–834
doi: 10.1586/14737167.2014.957683
Morrow GR, Navari RM, Rugo HS (2014) Clinical roundtable monograph: new data in emerging treatment options for chemotherapy-induced nausea and vomiting. Clin Adv Hematol Oncol 2(3 Suppl 9):1–14
Yennurajalingam S, Frisbee-Hume S, Palmer JL, Delgado-Guay MO, Bull J, Phan AT, Tannir NM, Litton JK, Reddy A, Hui D, Dalal S, Massie L, Reddy SK, Bruera E (2013) Reduction of cancer-related fatigue with dexamethasone: a double-blind, randomized, placebo-controlled trial in patients with advanced cancer. J Clin Oncol 31:3076–3082
doi: 10.1200/JCO.2012.44.4661
Matsuo N, Morita T, Matsuda Y et al (2016) Predictors of responses to corticosteroids for cancer-related fatigue in advanced cancer patients: a multicenter, prospective, observational study. J Pain Symptom Manage 52(1):64–72